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Cardiovascular diseases are one of the leading causes of morbidity and mortality. In
recent researches, it is demonstrated that microRNAs (miRNAs) are expressed exten-
sively in cardiovascular system and regulate gene expression in various cardiovascular
diseases. Here, we are giving overview on number of miRNAs involved in patho-
physiology of various cardiovascular diseases, and diagnostic and therapeutic potentials
of miRNAs in these diseases. MiRNAs are a group of small non-coding mRNAs with
approximately 18–22 nucleotides in length that regulate gene expression post tran-
scriptionally. MiRNAs are regulated in various cardiovascular diseases like hyperten-
sion, congestive heart failure, congenital heart defects, coronary artery disease and
stroke. Some of these miRNAs also act as potential biomarker of these cardiovascular
diseases. Inhibition of these miRNAs via different approaches like chemically modiﬁed
antisense oligonucleotide, antagomirs, and locked nucleic acids serves as effective
approaches for inactivating pathological miRNAs. Clinical trials are being conducted on
therapeutic and diagnostic potentials of miRNAs. However, extensive researches are
required to explore the therapeutic and diagnostic values of miRNAs as successful as
classical approaches.1. Introduction
The heart is among the most susceptible organs to birth
defects. About 1% of newborns suffer with heart malforma-
tion[1]. Moreover, one of the leading causes of morbidity and
mortality in adults is cardiovascular disease[1,2]. According to
the report of Centers for Disease Control and Prevention and
the National Health and Nutrition Examination Survey III,
about 47% of death is contributed to cardiovascular diseases.
Cardiovascular diseases include hypertension, coronary artery
disease (CAD), congestive heart failure (CHF), congenital
cardiovascular defects and stroke. The physiological and
pathological process of heart brings alteration in gene
expression[3]. MicroRNAs (miRNAs) have recently emerged
to exhibit powerful and unexpected role in variouscardiovascular diseases[4,5]. MiRNAs are a group of small
non-coding mRNAs with approximately 22 nucleotides[6].
MiRNAs are encoded with different types of genes and the
ones having major portions are called intergenic miRNAs
and intragenic miRNAs. RNA polymerase II is responsible
for transcription of miRNA and forms long primary miRNAs
(pri-miRNAs)[6,7]. These pri-miRNAs are processed by nu-
clear RNAase endonuclease III (Drosha) which forms precur-
sor miRNAs (pre-miRNA) containing 60–100 nucleotides.
Drosha is associated with DGCR8 (co-factor of Drosha) and
the combination of Drosha and DGCR8 is called “micropro-
cessor”. It may be indicated that these two play a signiﬁcant
role in miRNA processing[8]. The pre-miRNAs formed from
intergenic miRNAs are moved out of nucleus to cytoplasm
with help of exportin-5. In cytoplasm, RNAase endonuclease-
III (Dicer) further carries out processing of pre-miRNA to
generate mature miRNAs which contain around 22 nucleotide
units[9].
Development of heart begins with the formation of two
endocardial tubes. Fusion of these two endocardial tubes leads to
formation of primitive heart tube that septates into four cham-
bers and paired arterial trunks to form adult heart[10]. Differentarticle under the CC BY-NC-ND license
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For example, miR-218 promotes heart ﬁeld fusion and trans-
forms cardiac crescent to linear heart tube, miR-138 promotes
heart looping and atrioventricular canal development from linear
heart tube, miR-1, miR-133 and miR-17-92 clusters carry out
embryonic heart maturation and septation, and miR-15 promotes
post-natal heart growth and maturation[11]. Cardiac muscle is
enriched with miR-1, and it accounts for approximately 40%
of all miRNAs in myocardium[12]. In vertebrates, miR-1 and
miR-133 originate from common biscistronic transcript[13], and
clusters of both i.e. miR-1-1/133a-2 and miR-1-2/133a-1 are
highly expressed in myocardium[14]. MiR-15, miR-133, miR-
199, miR-590 are involved in cardiomyocyte proliferation.
MiR-133, miR-1, and miR-499 are involved in stem and pro-
genitor cell differentiation. MiR-133, miR-1, miR-499 and miR-
208 are involved in direct reprogramming i.e. ﬁbroblast to
myocytes[11]. Cardiac progenitor cell differentiation is enhanced
by expression of miR-499[15]. Myocardial progenitor
differentiation is also found to be enhanced by miR-17-92
clusters[16]. Similarly, miR-138 is involved in patterning of
chambers and valve region[17]. The importance of miRNAs in
cardiogenesis is also revealed by germline deletion of miR-1-2
and miR-126 resulting in ventricular septal defects and
vascular leakage, respectively[18]. MiR-21 appears to be
expressed in valvular endothelium and is necessary for devel-
opment of atrioventricular valve[19]. MiR-208a was found to be
important in proper development of the cardiac conduction
system[15].
Due to involvement of miRNAs at various levels of cardiac
development, up regulation and down regulation of miRNAs via
various mechanisms are known to be involved in cardiovascular
diseases. This review emphasizes the involvement of different
miRNAs in cardiovascular disease.
2. MiRNAs in hypertension
Several researches showed that miRNAs were known to
inﬂuence the condition of hypertension directly or indirectly.Table 1
MiRNAs in cardiovascular diseases.
Cardiovascular
disease
MiRNAs upregulated
Hypertension Human cytomegalovirus-miR-UL112, miR-605
623, miR-let-7e,
miR-516b, miR-600, kshv-miR-K12-6-3p, miR
miR-1252,
miR-27, miR-322, miR-451
Congenital heart
disease
Has-miR-498, miR-196a
CHF MiR-423-5p, miR-320a, miR-22, miR-92b, mi
miR-129-3p,
miR-3155, miR-3175, miR-583, miR-568, miR
miR-200a-star,
miR-1979, miR-371-3p, miR-155-star, miR-50
miR-100
Stroke Let-7b, miR-125b-2, miR-27a, miR-422a, miR
miR-627, miR-107In a research, 60 hypertensive patients and 29 healthy in-
dividuals were studied for assessment of miRNAs-9 and
miRNAs-126 levels. Levels of both these miRNAs were
lowered in hypertensive patients compared to healthy
control[20,21].
In another research, it was found that 46 miRNAs were
expressed in hypertensive patients compared with healthy in-
dividuals, among which 27 miRNAs were further detected
(Table 1). Among these 27 miRNAs, 9 miRNAs were upregu-
lated i.e. human cytomegalovirus-miR-UL112, miR-605, miR-
623, miR-let-7e, miR-516b, miR-600, kshv-miR-K12-6-3p,
miR-602 and miR-1252. About 18 miRNAs were down-
regulated: miR-296-5p, miR-133b, miR-625, miR-1236, miR-
518b, miR-1227, miR-615-5p, miR-18b, miR-1249, miR-324-
3p, ebv-miR-BART17-3p, ebv-miR-BART19-5p, kshv-miR-
K12-10a, kshv-miR-K12-10b, miR-4865p, miR-30d, miR-664
and miR-634 21. MiR-let-7a and miR-206 are known to be
involved in hypertension[22].
Exercise is a highly recommended lifestyle for hypertensive
patients. In research, it was found that exercise may alter the
expression of speciﬁc miRNAs targeting RAS genes. Results in
the same research demonstrated that decrease in miR-143
expression enhanced cardioprotective genes and miR-27 in
heart which was an inhibitor of angiotensin converting
enzymes[23].
Some miRNAs contribute to vascular remodeling which
perpetuates hypertension[24], like miR-130a, which inhibits the
growth arrest-speciﬁc homeobox and regulates vascular smooth
muscle cells contributing to vascular remodeling in
hypertension[25].
Pulmonary arterial hypertension which is characterized by
elevated pulmonary artery pressure to levels in systemic cir-
culation is also not away from alteration in some speciﬁc
miRNAs. In a published research, it was shown that miR-22
and miR-30 levels were decreased whereas miR-322 and
miR-451 were increased during the development of pulmonary
arterial hypertension in hypoxic and monocrotaline model[25,26].
MiR-30 is known to play a role in extracellular matrixMiRNAs downregulated
, miR-
-602
MiR-296-5p, miR-133b, miR-625, miR-1236, miR-
518b, miR-1227, miR-615-5p,
miR-18b, miR-1249, miR-324-3p, ebv-miR-BART17-
3p, ebv-miR-BART19-5p,
kshv-miR-K12-10a, kshv-miR-K12-10b, miR-4865p,
miR-30d, miR-664, miR-634,
miR-9, miR-126, miR-143, miR-22, miR-30
Has-let-7e-5p, has-miR-155-5p, has-miR-222-3p, has-
miR-433, has-miR-487b miR-421
R-122,
-30d,
25p,
MiR-107, miR-139, miR-142-5p, miR-126, miR-21,
miR-4278, miR-650,
miR744star, miR-516-5p, miR-1292, miR-182, miR-
1228, miR-595, miR-663b,
miR1296, miR-1825, miR-299-3p, miR-662 miR-122-
star, miR-3148,
miR-518e-star, miR-2054, miR-92
-488, MiR-301, miR-126
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model of pulmonary hypertension[27]. MiR-759 is also known
to be involved in chronic thromboembolic pulmonary
hypertension[28].
3. MiRNAs in CAD
Circulating miRNAs are biomarkers of CAD. Some miRNAs
are increased while some are decreased. Endothelially expressed
miR-126, miR-92a, miR-17, miR-145, miR-155, miR-208 and
miR-133a are decreased in CAD[29]. In a research, it was
demonstrated that reduction of endothelially expressed
miRNAs may be attributed to uptake into atherosclerotic
lesions within the vasculature of CAD patients[26,30]. Smooth
muscle-enriched miR-145 was also reduced in patients with
CAD. Cardiac muscle-enriched miRNAs, miR-133 and miR-
208a, were increased in patients with CAD[30]. Patients with
CAD have increased levels of miR-221 and miR-222 in endo-
thelial progenitor cells (EPCs), and these miRNAs bring about
mobilization of EPCs[26,30].
Apart from direct regulating condition of CAD, miRNAs
are involved indirectly as well. For example, it was shown in
study that oxidative stress defences in human EPCs are regu-
lated by miR-21. The authors induced dysfunctioning in hu-
man EPCs by using asymmetrical dimethylarginine, an
endogenous nitric oxide synthetase inhibitor, and they found
that miRNA-21 was up regulated which led to extracellular
signal regulated kinases-mitogen activated protein kinase-
dependant reactive oxygen species production and EPC
migratory defect, and also reduced NO bioavailability[31]. That
leads to endothelial dysfunction with increased risk of
cardiovascular disease with established CAD[32]. Antagonism
of miR-21 improves dysfunctional angiogenic progenitor
cells in CAD patients[33]. These ﬁndings suggested that
antagonism of miR-21 can be considered as potential thera-
peutic target in CAD patients[30,33].
4. MiRNAs in congenital heart disease (CHD)
One of the most occurring congenital anomalies in newborns
is CHD affecting about 1.35 million infants worldwide[34]. CHDs
include ventricular septal defect (VSD), atrial septal defect,
patent ductus arteriosus, tetralogy of Fallot, pulmonary valve
atresia, coarctation of the aorta and tricuspid atresia[35–38]. VSD
is one of the most common CHDs. In a research, 36 miRNAs
were found in patients with VSDs. Among these, 8 miRNAs
were validated to be expressed between VSD samples and
control sample. Among these eight miRNAs, seven were
downregulated: has-let-7e-5p, has-miR-155-5p, has-miR-222-
3p, has-miR-433, has-miR-487b and one upregulated: has-
miR-498[36].
Tetralogy of Fallot is a type of CHD which involves four
anatomical abnormalities of heart[39], i.e. pulmonary infundibular
stenosis, overriding aorta, ventricular septal defect and right
ventricular hypertrophy[40]. MiR-421 was found to be highly
expressed in right ventricle of infants with tetralogy of Fallot. In
a research, it was concluded that dysregulation of miR-421 in
infant heart tissue had negative impact of SOX-4, a key regulator
of Notch and Wnt pathway[40]. Activities of Notch and Wntpathway are closely intertwined during embryonic
development[41]. Hence, dysregulation of miR-421 contributes
to congenital defects[40].
In a research, 52 target gene of 16 miRNAs, targets of hsa-
miR-650 and targets of hsa-miR-650 showed the highest de-
gree of association with CHDs[34].
HOX gene clusters are involved in cardiac septation to valve
formation in different species. MiR-196a is expressed in HOX
gene clusters in mammals and was found to upregulate HOXb8
in context of limb development. Furthermore, level of miR-196a
was found to be increased in fetal heart sample as compared to
adult one[42].
5. MiRNAs in CHF
In a research, 186 miRNAs were screened in serum of heart
failure patients. Among these 186 miRNAs, four miRNAs i.e.
miR-423-5p, miR-320a, miR-22 and miR-92b, were found to be
increased in serum of heart failure patients. In the same research,
signiﬁcant association was revealed between miRNAs and
prognostic parameters like elevated serum brain natriuretic
peptide level, a wide QRS, and dilatation of the left ventricle and
left atrium[43].
In a study, plasma from 12 CHF patients were compared
with 12 healthy subjects by using microarray method, which
revealed expression of 108 miRNAs in CHF patients. Among
these 108 miRNAs, miR-423-5p was highly expressed in
CHF. The endothelial-enriched miR-126 was negatively
correlated with heart failure in patients. Also, decreased
levels of miR-107, miR-139 and miR-142-5p were displayed
in heart failure conditions. Interestingly, liver speciﬁc
miRNA, miR-122, was reported to elevate in heart failure
patients[44].
Changes in remodeling process, like left ventricular hy-
pertrophy and dilatation, take place in patients with CHF. In a
study, relationship between expression of miRNAs and electro
cardio gram parameters related to left ventricular mass index
(LVMI) was investigated in patients with CHF. Results in this
study demonstrated that 29 miRNAs were altered in CHF
patients. Among these 29 miRNAs, three miRNAs, i.e. miR-
182, miR-200a-star and miR-568, were found to have in-
verse correlation with LVMI, and two miRNAs i.e. miR-155
and miR-595 were found to have direct correlation with
LVMI[45].
Another published research by using microarray proﬁling
method in CHF patients showed upregulation of 18 miRNAs:
miR-21, miR-4278, miR-650, miR744star, miR-516-5p, miR-
1292, miR-182, miR-1228, miR-595, miR-663b, miR1296,
miR-1825, miR-299-3p, miR-662, miR-122-star, miR-3148,
miR-518e-star, and miR-2054, and downregulation of 11 miR-
NAs: miR-129-3p, miR-3155, miR-3175, miR-583, miR-568,
miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-
star, and miR-5025p[46].
Endo et al. focused his study on miR-210 which can be
biomarker of CHF, since it is known to be induced by hypoxia.
He concluded in his study that increase in plasma level of miR-
210 represented discrepancy between the pump function of heart
and oxygen demand in peripheral tissue and hence it can be a
new biomarker for chronic heart failure[47].
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expression of miR-195 in mice was sufﬁcient to induce patho-
logical cardiac growth and heart failure. The expression of miR-
100 is increased in the failing heart. Unlike miR-100, miR-92 is
downregulated in heart failure[48].
With the help of three mouse models of heart failure:
adrenergic receptor transgenic mice, C57BL/6 mice undergone
transverse aortic constriction, and C57BL/6 mice treated with
isopropanol, Vettori et al. demonstrated that miR-21 was upre-
gulated in heart failure[49].6. MiRNAs in stroke
Stroke is responsible for 10% of deaths worldwide and is one
of the leading causes of disability. MiRNAs are involved in
stroke risk factors including hypertension, atherosclerosis, atrial
ﬁbrillation, diabetes and dyslipidemia[50].
MiRNAs like miR-21, miR-221 and miR-145 are known to
be associated with cardiovascular system. On the basis of this,
levels of these three miRNAs were evaluated in patients with
stroke. Regression models containing serum miRNA level and
risk factor were used for the prediction for stroke. Results in this
study demonstrated that miR-21 and miR-222 were novel bio-
markers of stroke but miR-145 were not[51].
By real-time PCR technique, levels of miRNAs were
quantiﬁed in 197 patients with ischemic stroke at interval of
24 h, 1 week, 4 weeks and 48 weeks. For control, 50 healthy
volunteers were selected. Results showed that circulating levels
of miR-301 and miR-126 were downregulated whereas let-7b
was upregulated in ischemic stroke patients until 24 weeks.
However, levels of these miRNAs were normalized 48 weeks
after the symptom onset. Further, the researchers concluded
that miR-30a, miR-126 and let-7b acted as biomarkers of
ischemic stroke[52].
In a study, it was reported that panel of 32 miRNAs was
identiﬁed in stroke subtypes based on stroke patients' blood
miRNAs proﬁle. Consistent upregulation of miR-125b-2, miR-
27a, miR-422a, miR-488 and miR-627 was found during
ischemic stroke. Thus, it was concluded that these miRNAs
served with diagnostic value and reﬂected onset of ischemic
stroke[53].
Some miRNAs like miR-298, miR-155, and miR-362-3p
may be altered more than 2 folds. Elevation of some miRNAs
or miRNA mimics has been used as a factor by many scientists
to treat experimental stroke. For example, lenti-miR-424 treat-
ment decreased ischemic stroke. Similarly, insertion of miR-17-
92 increased cell proliferation in stroke. MiR-223 has a thera-
peutic role in stroke[54].
In a study, plasma levels of miR-107 and glutamate were
elevated proportionally in patients with ischemic stroke. Hence,
miR-107 plasma level may act as a biomarker for monitoring
excitotoxicity with ischemic stroke patients[55].7. Therapeutic and diagnostic potentials of miRNAs
MiRNAs play a signiﬁcant role in growth and development
of heart. Also, miRNAs are expressed extensively in normal aswell as diseased heart. Hence, miRNAs may serve as a po-
tential diagnostic tool for monitoring cardiovascular dis-
eases[56]. MiRNA targets differ from classical approaches of
drug development. Since, classical approaches have high
speciﬁcity for single targets whereas single miRNAs have
multiple targets, and modulating the expression of single
miRNA can inﬂuence an entire gene network[57,58]. Other
challenges of using miRNAs as diagnostic and therapeutic
tool are modes of delivery, speciﬁcity, toxicity, reversibility
and regulation[59].
Recently, many miRNAs serve to be biomarkers of car-
diovascular diseases. For example, the circulating miR-1 is
signiﬁcantly higher in patients with acute myocardial infarc-
tion[60]. Similarly, plasma concentration of miR423-5p is
higher in heart failure patients but not in healthy people[61].
MiRNAs not only serve as diagnostic markers, but their
expression can also be modulated by using anti- or mimic
miRNAs in pathological conditions. For example, miR-21
mimic is demonstrated to impart the same neuroprotection as
miR-21[62].
Inhibition of miRNAs serves as effective technique for
inactivating pathological miRNAs. Chemically modiﬁed anti-
sense oligonucleotide and antagomirs are extensively used tools
to modify miRNAs, and it is found to be an effective therapeutic
approach for treatment of certain disease[61]. For example,
infusion of an antagomir-145 that targets miR-145, decreases
cortical infarcts[62]. Similarly, locked nucleic acids (LNAs)
(analogs of RNAs) are also used for inhibition of miRNAs.
For hepatitis-C treatment, a LNAs-based anti-miRNA was
developed which speciﬁcally acted against liver speciﬁc miR-
122, and this anti-miRNA can also be utilized in cardiovascu-
lar disease, since miR-122 also regulates plasma cholesterol
level[63].
Global miRNA research market is one of the most valued
markets nowadays. According to BCC research report 2014, the
global market for miRNAs research tools was valued at 478.8
million dollars in 2013 and is expected to reach 1 billion dollars
in 2019[64]. Several companies involved in miRNA therapeutics
are listed in Table 2[65–74].8. Conclusions
The review provides evidence that miRNAs play an impor-
tant role in growth and development of heart as well as in
different pathological conditions of heart. Several miRNAs are
altered and act as biomarkers of these conditions while antag-
onism of some miRNAs via different techniques like LNAs and
antisense oligonucleotide is required for prevention of these
pathological threats. However, shortcomings are needed to be
resolved in understanding miRNAs-based regulation of gene
expression. For example, as mentioned earlier that single
miRNA has multiple targets, hence, it is necessary but quite
challenging to ﬁnd out the exact mechanism and pathway fol-
lowed by these miRNAs. Therefore, it is necessary to deﬁne
roles of individual miRNAs and its important target, in different
settings based on cell types and pathological implication. One
more hurdle that needs consideration, is in-vivo delivery of
miRNAs-based therapeutics. Thus, extensive researches on miR-
Table 2
Commercial development in miRNA therapeutics.
Name of
company
Product MicroRNA target Implication Stage of development Reference
Santaris Pharma Miravirsen
(SPC3649)
Inhibitor of miR-122 Hepatitis C Phase II [65]
Regulus
therapeutics
RG-101 Inhibitor of miR-122 Hepatitis C Expect to initiate Phase II [66]
RG-012 Inhibitor of miR-21 Alport syndrome Expect to initiate Phase I [67]
RG-125 Inhibitor of miR-103/107 Non-alcoholic steatohepatitis
with
type 2 diabetes/prediabetes
Expect to initiate Phase I [68]
Not speciﬁed Inhibits miR-133a/b Atherosclerosis Preclinical stage [69]
Not speciﬁed Inhibits miR-10b Suppression of lung
metastasis
from breast tumours,
inhibition
of neuroblastoma
Preclinical stage [69]
Not speciﬁed Inhibition of miR-350-5p Inhibition of neuroblastoma Preclinical stage [69]
Marina Biotech MRX34 Mimic of miR-34 Haematological malignancy Phase I ongoing, dose of
Phase II decided
[70,71]
MiRNA
Therapeutics
MRX34 Mimic of miR-34 Primary liver cancers and
solid
cancer with liver metastasis
Phase I [72]
MiR-Rxlet-7 Let-7 mimic Not speciﬁed Preclinical stage [72]
MiR-Rx-06 Mimic of miR-16 Not speciﬁed In-vivo formulation [72]
MiR-Rx-06 Undisclosed Not speciﬁed In-vivo formulation [72]
MiR-Rx07 Undisclosed Not speciﬁed In-vivo formulation [72]
Rosetta Genomics MiR-34a mimetic MiR 34a and p53 Cancer and liver infection Preclinical stage [73,74]
MiRagen
therapeutics
Not speciﬁed Inhibition of miR-155 Haematological
malignancies
IND enabling
Not speciﬁed Inhibition of miR-155 Amyotrophic lateral
sclerosis
IND enabling
Not speciﬁed Inhibition of miR-29 Cutaneous and pulmonary
ﬁbrosis
IND enabling
Not speciﬁed Inhibition of miR-92a Peripheral artery disease Preclinical stage [69]
MGN-9103 Inhibition of miR-208 Chronic heart failure Preclinical stage [69]
MGN-1374 Inhibition of miR-15
and miR-195
Postnatal cell cycle arrest in
heart
generation after myocardial
infarction
Preclinical stage [69]
MGN-4893 Inhibition of miR-451 Polycythemia vera Preclinical stage [69]
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and prevention of cardiovascular diseases. However, many as-
pects in miRNAs-based diagnostic and therapeutic tool are still
awaiting discovery to make it as successful as conventional
therapy.Conﬂict of interest statement
The authors report no conﬂict of interest.
References
[1] Latronico MV, Catalucci D, Condorelli G. Emerging role of
microRNAs in cardiovascular biology. Circ Res 2007; 101(12):
1225-36.
[2] Yang B, Lu Y, Wang Z. Control of cardiac excitability by
microRNAs. Cardiovasc Res 2008; 79(4): 571-80.
[3] American Heart Association. 2000 heart and stroke statistical
update. Dallas (TX): American Heart Association; 2000.
[4] El-Armouche A, Schwoerer AP, Neuber C, Emmons J, Biermann D,
Christalla T, et al. Correction: common microRNA signatures in
cardiac hypertrophic and atrophic remodeling induced by changes in
hemodynamic load. PLoS One 2011; http://dx.doi.org/10.1371/
annotation/45ab2d79-0ce9-4832-a0d1-5274b5a1ddaa.[5] van Rooij E, Marshall WS, Olson EN. Toward microRNA-based
therapeutics for heart disease: the sense in antisense. Circ Res
2008; 103(9): 919-28.
[6] Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A,
Brognara E, et al. Targeting microRNAs involved in human dis-
eases: a novel approach for modiﬁcation of gene expression and
drug development. Biochem Pharmacol 2011; 82(10): 1416-29.
[7] Lynn FC. Meta-regulation: microRNA regulation of glucose and
lipid metabolism. Trends Endocrinol Metab 2009; 20(9): 452-9.
[8] Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, et al. Mo-
lecular basis for the recognition of primary microRNAs by Drosha-
DGCR8 complex. Cell 2006; 125(5): 887-901.
[9] Vermeulen A, Behlen L, Reynolds A, Wolfson A, Marshall WS,
Karpilow J, et al. The contributions of dsRNA structure to Dicer
speciﬁcity and efﬁciency. RNA 2005; 11(5): 674-82.
[10] Moorman A, Webb S, Brown NA, Lamers W, Anderson RH.
Development of the heart: (1) formation of cardiac chambers and
arterial trunks. Heart 2003; 89(7): 806-14.
[11] Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL,
et al. MicroRNA-206 delays ALS progression and promotes
regeneration of neuromuscular synapses in mice. Science 2009;
326(5959): 1549-54.
[12] Fuller AM, Qian L. MiRiad roles for microRNAs in cardiac
development and regeneration. Cells 2014; 3(3): 724-50.
[13] Liu N, Olson EN. MicroRNA regulatory networks in cardiovas-
cular development. Dev Cell 2010; 18(4): 510-25.
[14] Porrello ER. MicroRNAs in cardiac development and regeneration.
Clin Sci (Lond) 2013; 125(4): 151-66.
Syed Salman Ali et al./Journal of Acute Disease 2016; 5(1): 9–1514[15] Ostadal B, Dhalla NS. Cardiac adaptations. Molecular mecha-
nisms (advances in biochemistry in health and disease). Vol. 4.
New York: Springer; 2013.
[16] Wang J, Greene SB, Bonilla-Claudio M, Tao Y, Zhang J, Bai Y,
et al. Bmp signalling regulates myocardial differentiation from
cardiac progenitors through a microRNA-mediated mechanism.
Dev Cell 2010; 19(6): 903-12.
[17] Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular
development. Circ Res 2009; 104(6): 724-32.
[18] Bonet F, Hernandez-Torres F, Esteban FJ, Aranega A, Franco D.
Comparative analyses of microRNA microarrays during cardio-
genesis: functional perspectives. Microarrays 2013; 2(2): 81-96.
[19] Kolpa HJ, Peal DS, Lynch SN, Giokas AC, Ghatak S, Misra S,
et al. MiR-21 represses Pdcd4 during cardiac valvulogenesis.
Development 2013; 140(10): 2172-80.
[20] Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI,
Vardas PE. MicroRNA-9 and microRNA-126 expression levels in
patients with essential hypertension: potential markers of target-
organ damage. J Am Soc Hypertens 2014; 8(6): 368-75.
[21] Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, et al.
Signature microRNA expression proﬁle of essential hypertension
and its novel link to human cytomegalovirus infection. Circulation
2011; 124(2): 175-84.
[22] Da Costa Martins PA, De Windt LJ. MicroRNAs in control of
cardiac hypertrophy. Cardiovasc Res 2012; 93(4): 563-72.
[23] Fernandes T, Hashimoto NY, Magalhães FC, Fernandes FB,
Casarini DE, Carmona AK, et al. Aerobic exercise training-induced
left ventricular hypertrophy involves regulatory MicroRNAs,
decreased angiotensin-converting enzyme-angiotensin II, and syn-
ergistic regulation of angiotensin-converting enzyme 2-angiotensin
(1-7). Hypertension 2011; 58(2): 182-9.
[24] Renna NF, de Las Heras N, Miatello RM. Pathophysiology of
vascular remodeling in hypertension. Int J Hypertens 2013; 2013:
808353.
[25] Wu WH, Hu CP, Chen XP, Zhang WF, Li XW, Xiong XM, et al.
MicroRNAs-130a mediates proliferation of vascular smooth
muscle cells in hypertension. Am J Hypertens 2011; 24(10):
1087-93.
[26] Jamaluddin MS, Weakley SM, Zhang L, Kougias P, Lin PH,
Yao Q, et al. MiRNAs: roles and clinical applications in vascular
disease. Expert Rev Mol Diagn 2011; 11(1): 79-89.
[27] Caruso P, MacLean MR, Khanin R, McClure J, Soon E,
Southgate M, et al. Dynamic changes in lung microRNA proﬁles
during development of pulmonary hypertension due to chronic
hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010;
30(4): 716-23.
[28] Chen Z, Nakajima T, Tanabe N, Hinohara K, Sakao S, Kasahara Y,
et al. Susceptibility to chronic thromboembolic pulmonary hyper-
tension may be conferred by miR-759 via its targeted interaction
with polymorphic ﬁbrinogen a gene. Hum Genet 2010; 128(4):
443-52.
[29] Contu R, Latronico MV, Condorelli G. Circulating microRNAs as
potential biomarkers of coronary artery disease: a promise to be
fulﬁlled? Circ Res 2010; 107(5): 573-4.
[30] Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A,
Liebetrau C, et al. Circulating microRNAs in patients with coro-
nary artery disease. Circ Res 2010; 107(5): 677-84.
[31] Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, et al.
Short communication: asymmetric dimethylarginine impairs
angiogenic progenitor cell function in patients with coronary artery
disease through a microRNA-21-dependent mechanism. Circ Res
2010; 107(1): 138-43.
[32] Bo¨ger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R,
Benjamin EJ, et al. Plasma asymmetric dimethylarginine and
incidence of cardiovascular disease and death in the community.
Circulation 2009; 119(12): 1592-600.
[33] Quintavalle M, Condorelli G, Elia L. Arterial remodeling and
atherosclerosis: miRNAs involvement. Vascul Pharmacol 2011;
55(4): 106-10.[34] Xing HJ, Li YJ, Ma QM, Wang AM, Wang JL, Sun M, et al.
Identiﬁcation of microRNAs present in congenital heart disease
associated copy number variants. Eur Rev Med Pharmacol Sci
2013; 17(15): 2114-20.
[35] Gao Y, Huang GY. Advances in the etiology of congenital heart
disease and epidemiological studies. Chin J Evid Based Pediatr
2008; 3: 213-22.
[36] Li D, Ji L, Liu L, Liu Y, Hou H, Yu K, et al. Characterization of
circulating miRNA expression in patients with a ventricular septal
defect. PLoS One 2014; 9(8): e106318.
[37] Breitbart RE, Fyler DC. Tetralogy of Fallot. In: Keane JF, Lock JE,
Fyler DC, editors. Nadas' pediatric cardiology. Philadelphia:
Saunders Elsevier; 2006.
[38] Gatzoulis MA, Webb GD, Daubeney PEF. Diagnosis and man-
agement of adult congenital heart disease. Edinburgh: Churchill
Livingstone; 2003.
[39] Anderson RH, Tynan M. Tetralogy of Fallot-a centennial review.
Int J Cardiol 1988; 21(3): 219-32.
[40] Bittel DC, Kibiryeva N, Marshall JA, O'Brien JE. MicroRNA-421
dysregulation is associated with tetralogy of Fallot. Cells 2014;
3(3): 713-23.
[41] Hayward P, Kalmar T, Arias AM. Wnt/Notch signalling and in-
formation processing during development. Development 2008;
135(3): 411-24.
[42] Wang ZG. MicroRNAs and cardiovascular disease. Oak Park:
Bentham Science Publishers; 2010.
[43] Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum
levels of microRNAs in patients with heart failure. Eur J Heart Fail
2012; 14(2): 147-54.
[44] van Empel VP, De Windt LJ, da Costa Martins PA. Circulating
miRNAs: reﬂecting or affecting cardiovascular disease? Curr
Hypertens Rep 2012; 14(6): 498-509.
[45] Cakmak HA, Barman HA, Ikitimur B, Coskunpinar E,
Oltulu YM, Can G, et al. The assessment of relationship between
dysregulated microRNAs and left ventricular mass and mass
index in systolic heart failure. J Am Coll Cardiol 2013;
62(18 Suppl 2): C17.
[46] Cakmak HA, Barman HA, Coskunpinar E, Oltulu YM, Ikitimur B,
Can G, et al. The diagnostic importance of microRNAs in
congestive heart failure. J Am Coll Cardiol 2013; 62(18 Suppl 2):
C17-8.
[47] Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, et al.
MicroRNA 210 as a biomarker for congestive heart failure. Biol
Pharm Bull 2013; 36(1): 48-54.
[48] Wang N, Zhou Z, Liao X, Zhang T. Role of microRNAs in cardiac
hypertrophy and heart failure. IUBMB Life 2009; 61(6): 566-71.
[49] Vettori S, Gay S, Distler O. Role of microRNAs in ﬁbrosis. Open
Rheumatol J 2012; 6: 130-9.
[50] Koutsis G, Siasos G, Spengos K. The emerging role of microRNA
in stroke. Curr Top Med Chem 2013; 13(13): 1573-88.
[51] Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT, Juo SH. Serum
microRNA-21 and microRNA-221 as potential biomarkers for
cerebrovascular disease. J Vasc Res 2013; 50(4): 346-54.
[52] Long G, Wang F, Li H, Yin Z, Sandip C, Lou Y, et al. Circulating
miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in
humans. BMC Neurol 2013; 13: 178.
[53] Sepramaniam S, Tan JR, Tan KS, DeSilva DA, Tavintharan S,
Woon FP, et al. Circulating microRNAs as biomarkers of acute
stroke. Int J Mol Sci 2014; 15(1): 1418-32.
[54] Li Y, Liu Y, Wang Z, Hou H, Lin Y, Jiang Y. MicroRNA: not far
from clinical application in ischemic stroke. Int Schol Res Not
Stroke 2013; http://dx.doi.org/10.1155/2013/858945.
[55] Yang ZB, Zhang Z, Li TB, Lou Z, Li SY, Yang H, et al. Up-
regulation of brain-enriched miR-107 promotes excitatory neuro-
toxicity through down-regulation of glutamate transporter-1
expression following ischaemic stroke. Clin Sci (Lond) 2014;
127(12): 679-89.
[56] van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J,
Gerard RD, et al. A signature pattern of stress-responsive
Syed Salman Ali et al./Journal of Acute Disease 2016; 5(1): 9–15 15microRNAs that can evoke cardiac hypertrophy and heart failure.
Proc Natl Acad Sci USA 2006; 103(48): 18255-60.
[57] van Rooij E, Olson EN. MicroRNAs: powerful new regulators of
heart disease and provocative therapeutic targets. J Clin Invest
2007; 117(9): 2369-76.
[58] Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating
microRNA-1 as a potential novel biomarker for acute myocardial
infarction. Biochem Biophys Res Commun 2010; 391(1): 73-7.
[59] Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der
Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for
heart failure. Circ Res 2010; 106(6): 1035-9.
[60] Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA
expression signature and antisense-mediated depletion reveal an
essential role of microRNA in vascular neointimal lesion forma-
tion. Circ Res 2007; 100(11): 1579-88.
[61] Davis S, Propp S, Freier SM, Jones LE, Serra MJ, Kinberger G,
et al. Potent inhibition of microRNA in vivo without degradation.
Nucleic Acids Res 2009; 37(1): 70-7.
[62] Dharap A, Bowen K, Place R, Li LC, Vemuganti R. Transient focal
ischemia induces extensive temporal changes in rat cerebral
microRNAome. J Cereb Blood Flow Metab 2009; 29(4): 675-87.
[63] Torres AG, Fabani MM, Vigorito E, Gait MJ. MicroRNA fate upon
targeting with anti-miRNA oligonucleotides as revealed by an
improved Northern-blot-based method for miRNA detection. RNA
2011; 17(5): 933-43.
[64] BCC Research LLC. MicroRNA research tools, diagnostics and
therapeutics: global markets. Report code: BIO115B. Wellesley:
BCC Research LLC; 2014. [Online] Available from: http://www.
bccresearch.com/market-research/biotechnology/microRNA-
research-tools-diagnostics-therapeutics-report-bio115b.html
[Accessed on 24th March, 2015]
[65] Lindow M, Kauppinen S. Discovering the ﬁrst microRNA-targeted
drug. J Cell Biol 2012; 199(3): 407-12.
[66] Bhat B, Neben S, Tay J, Liu K, Chau N, Hogan D, et al. RG-101, a
GaINAC-conjugated anti-miR employing a unique mechanism of
action by targeting host factor MicroRNA-122 (miR-122), dem-
onstrates potent activity and reduction of HCV in preclinical
studies. Hepatology 2013; 58(6): 1393A.
[67] Regulus Therapeutics Inc. Regulus receives orphan drug designation
for RG-012, a microRNA therapeutic for the treatment of Alportsyndrome. San Diego: Regulus Therapeutics Inc.; 2014. [Online]
Available from: http://www.regulusrx.com/regulus-receives-orphan-
drug-designation-for-rg-012-a-microrna-therapeutic-for-the-treat-
ment-of-alport-syndrome-2/ [Accessed on 30th March, 2015]
[68] Christoph. RG-125 (AZD4076), a microRNA therapeutic targeting
microRNA-103/107 for the treatment of NASH in patients with
type 2 diabetes/Pre-diabetic, selected as clinical candidate by
AstraZeneca. Regulus Therapeutics Inc. [Online]. Available from:
http://mirnablog.com/a-microrna-therapeutic-targeting-microrna-
103107-for-the-treatment-of-nash-in-patients-with-type-2-dia-
betespre-diabetes-selected-as-clinical-candidate-by-astrazeneca/
[Accessed on 5th April, 2015]
[69] Hydbring P, Badalian-Very G. Clinical application of microRNAs.
F1000Res 2013; http://dx.doi.org/10.12688/f1000research.2-
136.v3.
[70] Marina Biotech. Marina Biotech announces that licensee miRNA
therapeutics enrolls ﬁrst patientin hematologic malignancy cohort
of on-going trial. Boston: Marina Biotech, Inc.; 2014. [Online]
Available from: http://www.marinabio.com/ﬁles/2314/0856/
2070/14-06-12_-_Marina_Biotech_Announces_That_Licensee_
Mirna_Therapeutics_Enrolls_First_Patient_in_Hematologic_
Malignancy_Cohort_of_On-Going_Trial.pdf [Accessed on 5th
April, 2015]
[71] BioSpace. Marina Biotech reports that partner MiRNA therapeutics
presented interim phase 1 data on its ﬁrst-in-class microRNA-34
mimic. Colorado: BioSpace; 2014. [Online] Available from: http://
www.biospace.com/News/marina-biotech-inc-reports-that-partner-
mirna/355635 [Accessed on 4th April, 2015]
[72] MiRNA Therapeutics. Product development pipeline. Austin:
MiRNA Therapeutics; 2014. [Online] Available from: http://www.
mirnarx.com/pipeline/mirna-pipeline.html [Accessed on 6th April,
2015]
[73] Rosetta Genomics. Research programme: microRNA-targeted
therapeutics-Rosetta Genomics. Jersey: Rosetta Genomics; 2013.
[Online] Available from: http://adisinsight.springer.com/drugs/
800028935 [Accessed on 26th April, 2015]
[74] Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis,
mechanism, function, and recent clinical trials. Biochim Biophys
Acta 2010; 1803(11): 1231-43.
